Identifikation af non-kompliante hypertonikere Udvikling af screeningsredskab ved grafisk analyse Speciale udarbejdet af Marianne Maibøll & Marianne Agergaard Kandidatuddannelsen i Folkesundhedsvidenskab Københavns Universitet Vejledere Lektor Svend Kreiner, Institut for Folkesundhedsvidenskab, Københavns Universitet Cand.scient.san.publ. Pernille Dam, Pharmakon Januar 2008 1 Forord Hillerød, januar 2008 Dette speciale er udarbejdet i efteråret 2007. Data er stillet til rådighed af Pharmakon, der har stået for spørgeskemaudarbejdelse og dataindsamling. I forbindelse med metodevalg og vink- ling af opgaven har vi haft frie hænder. Der takkes for uvurderlig hjælp og støtte fra familie, venner og ansatte i afdeling APS på Phar- makon. Især takkes vejlederne Svend Kreiner og Pernille Dam for inspiration og optimisme. God læselyst. Marianne Maibøll Marianne Agergaard Opgavens omfang svarer til 118 normalsider 2 Resume Lægemiddel non-compliance opstår, når patienten ikke tager medicinen som ordineret. Non- compliance anses for en af de vigtigste årsager til ukontrolleret hypertension, med øget risiko for kardiovaskulære komplikationer til følge. Det har vist sig vanskeligt at screene for non- compliance, idet alle kendte metoder har svagheder. Formålet med opgaven er at udvikle et simpelt, præcist og validt screeningsredskab, der kan anvendes i den primære sundhedssektor til at identificere non-kompliante hypertensionspatien- ter. Udgangspunktet for analysen er spørgeskemadata fra 1421 hypertensionspatienter samt data fra patienternes medicinprofil (PEM; n = 182) og elektroniske medicinbeholdere (MEMS; n = 33). Analyserne foretages ved brug af grafiske Rasch-modeller og omfatter indledningsvis en skalavalidering af fire spørgsmålsgrupper. Heraf findes henholdsvis tre og fem valide og skaler- bare skalaer. Skalaerne anvendes i to efterfølgende multivariate multiple regressionsanalyser, hvor der inddrages henholdsvis 28 og 29 variable. Spørgsmålet ”Lå dit høje blodtryk over 140 mmHg sidste gang, du fik det målt?” (´systolisk BT´) viser sig at være central i kraft af dens korrelation med PEM og MEMS. De inddragne skalaer er alle signifikant forbundne og korrelerer med PEM via skalaen ´utilsigtet non-compliance´. Denne skala består af fem spørgsmål og vedrører patientens tilbøjelighed til at glemme indtagelsen af medicin. Desuden vises, at det kan være relevant at inddrage skalaen vedrørende bekymringer relateret til medicinindtagelsen (´medicinsk bekymring´) og skalaen vedrørende situationer, hvor patienten fravælger at følge lægemiddelordinationerne (’tilsigtet non-compliance’). På baggrund af de forskellige datakilder og antallet af variable inddraget i analyserne vurderes det, at scree- ningsredskabet er validt. Det konkluderes, at et simpelt og præcist screeningsredskab består af variablen ´systolisk BT´ og skalaen ´utilsigtet non-compliance´. Dette redskab kan, hvis det findes indholdsmæssigt re- levant og realiserbart, suppleres med skalaerne ´medicinsk bekymring´ og/eller ´tilsigtet non- compliance´. 3 Abstract Identification of non-adherent hypertensive patients – Development of a screening instrument using graphical models. Introduction: Medical non-compliance occur when patients do not take their medicines as directed. Poor compliance with antihypertensive medication is assumed to be an important reason for unsatisfactory control of blood pressure, which may result in severe cardiovascular complications. It is proven difficult to detect non-compliance as all known methods have weaknesses. The aim of the present study is developing a simple, precise and valid screening instrument for use in primary health care to identify hypertensive patients, who do not follow the prescriptions. Material and methods: The data consists of questionnaires obtained from 1421 hypertensive patients, together with pharmacy refill records (PEM; n = 182) and electronic monitors (MEMS; n = 33). The analysis is carried out using graphical Rasch-models and consist of validation of four multi-item scales and two regression analysis of respectively 28 and 29 variables. The Results: The regression analyses reveals strong significant correlations between the self- reported variable ´systolic BP´ (“Did your systolic blood pressure exceed 140 mmHg the last time, it was measured?”) and the measures of PEM and MEMS. The validated scales correlates with compliance according to PEM. The scale ´unintentional non-compliance´ consists of five questions concerning medication lapse. This scale connects to ´systolic BP´ in the graphical models. Furthermore it seems relevant to include either a scale regarding ´medical concerns´ and/or a scale describing situations in which the patient chooses to violate the prescriptions (´intentional non-compliance´). Due to the different data sources and many included variables related to compliance-behaviour, the analysis succeeded in creating a validated tool for screening patients. Conclusions: It can be concluded, that a simple and precise screening instrument should consist of the variable ´systolic BP´ and the scale ´unintentional non-compliance´. In case of relevance, including scales concerning ´medical concerns´ and/or ´intentional non-compliance´ can increase the sensitivity of the instrument. 4 Indholdsfortegnelse Forord..........................................................................................................................................................2 Resume........................................................................................................................................................3 Abstract.......................................................................................................................................................4 Liste over tabeller.......................................................................................................................................9 Liste over figurer......................................................................................................................................10 1 Indledning.........................................................................................................................................11 2 Problemformulering.........................................................................................................................14 2.1 Begrebsafklaring i relation til problemformuleringen.................................................................15 3 Specialets opbygning......................................................................................................................16 4 Introduktion til begrebet non-compliance.....................................................................................17 4.1 Compliance og non-compliance................................................................................................17 4.2 Non-compliance i relation til hypertension................................................................................17 4.3 Typer af non-compliance...........................................................................................................18 4.3.1 Tilsigtet non-compliance.......................................................................................................19 4.3.2 Utilsigtet non-compliance......................................................................................................19 4.4 Hvornår er en patient non-kompliant?.......................................................................................19 4.5 Metoder til screening for non-compliance.................................................................................21 4.5.1 Spørgeskema........................................................................................................................24 4.5.2 Personlig Elektronisk Medicinprofil (PEM)............................................................................25 4.5.3 Medication Event Monitoring System (MEMS).....................................................................26 4.5.4 Afsluttende kommentarer til screeningsmetoder..................................................................28 4.6 Årsager til non-compliance........................................................................................................28 4.6.1 Concordance (medindflydelse).............................................................................................30 4.6.2 Handlekompetence (´self-efficacy´)......................................................................................31 4.6.3 Egenindsats (´locus of control´ og ´self management´)........................................................31 4.7 Hvordan øges compliance-graden?..........................................................................................31 4.8 Opsummering............................................................................................................................33 5 Projektet ´Sikker og effektiv medicinbrug for brugere af blodtryksmedicin´............................34 5.1 Udvælgelse af deltagere...........................................................................................................34 5.2 Dataindsamling i projektforløbet...............................................................................................35 6 Skalavaliditet og skalerbarhed.......................................................................................................36 6.1 Validitet......................................................................................................................................36 6.1.1 Begrebsvaliditet (´construct validity´)....................................................................................36 6.1.2 Kriterievaliditet (´criterion validity´)........................................................................................37 6.1.3 Sensitivitet og ´responsiveness´...........................................................................................37 6.1.4 Indholdsvaliditet (´content validity´ og ’face validity’)............................................................37 6.2 Skalerbarhed.............................................................................................................................38 6.2.1 Reliabilitet.............................................................................................................................38 6.2.2 Cronbach’s alfa (α)...............................................................................................................38 6.2.3 Objektivitet............................................................................................................................39 6.2.4 Sufficiens..............................................................................................................................39 6.2.5 Generaliserbarhed................................................................................................................39 6.3 Afsluttende kommentar til validering og skalerbarhed..............................................................39 7 Item response theory (IRT).............................................................................................................41 7.1 Den latente variabel og sum-scoren.........................................................................................41 5 7.2 Egenskaber ved IRT.................................................................................................................42 7.3 Antagelser for IRT-modellerne..................................................................................................42 7.3.1 Lokal uafhængighed.............................................................................................................43 7.3.2 Unidimensionalitet................................................................................................................43 7.3.3 Fravær af DIF........................................................................................................................43 7.3.4 Monotonitet...........................................................................................................................44 7.4 Rasch modeller.........................................................................................................................44 7.4.1 Grafiske Rasch modeller (GRM)...........................................................................................45 7.4.2 Grafiske loglineære Rasch modeller (GLLRM).....................................................................45 7.4.3 Opsamling for de anvendte IRT-modeller.............................................................................46 8 Grafiske modeller.............................................................................................................................47 8.1.1 Den rekursive struktur...........................................................................................................47 8.1.2 Betinget uafhængighed.........................................................................................................47 8.1.3 Separations egenskaber.......................................................................................................47 9 Metode..............................................................................................................................................48 9.1 Indledende databehandling.......................................................................................................50 9.1.1 Udvælgelse af spørgeskemavariable...................................................................................50 9.1.2 PEM-data..............................................................................................................................57 9.1.3 MEMS-data...........................................................................................................................59 9.1.4 Frasortering af cases............................................................................................................61 9.1.5 Kategorisering af variable.....................................................................................................61 9.2 Introduktion til den statistiske analyse......................................................................................63 9.2.1 Egenskaber ved DIGRAM....................................................................................................63 9.3 Skalavalidering..........................................................................................................................65 9.3.1 Kvalitetskriterier for skalaerne..............................................................................................65 9.3.2 Fremgangsmåde...................................................................................................................66 9.3.3 Dannelse af skala med personestimater..............................................................................70 9.4 Multivariat analyse....................................................................................................................71 9.4.1 Definition af model................................................................................................................71 9.4.2 Analysestrategi.....................................................................................................................71 9.4.3 Endelig model.......................................................................................................................73 9.5 Opsummering af metoden.........................................................................................................74 10 Resultater.........................................................................................................................................75 10.1 Deskriptiv statistik.....................................................................................................................76 10.1.1 De subjektive data: Spørgeskemavariable.......................................................................76 10.1.2 De objektive data: PEM og MEMS...................................................................................79 10.2 Skalavalidering..........................................................................................................................82 10.2.1 Problemer med medicinen...............................................................................................83 10.2.2 Erfaringer med medicinen................................................................................................87 10.2.3 Din psykiske trivsel...........................................................................................................93 10.2.4 Din brug af medicin: Analyse 1.........................................................................................95 10.2.5 Din brug af medicin: Analyse 2.......................................................................................100 10.2.6 Opsummering af resultater fra skalavalideringen...........................................................107 10.3 Deskriptiv statistik: Skalaer.....................................................................................................109 10.4 Multivariat analyse..................................................................................................................113 10.4.1 Analyse 1........................................................................................................................114 10.4.2 Analyse 2........................................................................................................................118 10.5 Opsummering af resultater fra den grafiske regressionsanalyse...........................................122 11 Diskussion af datamateriale og metodevalg...............................................................................123 11.1 Udvælgelse af spørgeskemavariable......................................................................................123 11.1.1 Prioritering af variable....................................................................................................123 11.1.2 De eksogene variable som mulige confoundere............................................................124 11.1.3 Variablene ´systolisk BT´ og ´diastolisk BT´...................................................................124 11.1.4 Begrænsninger på grund af frasorteringen af variable...................................................126 6 11.1.5 Afsluttende kommentarer til udvælgelsen af variable....................................................126 11.2 Direkte og indirekte formulerede spørgsmål...........................................................................127 11.3 Variabel- og skalanavne..........................................................................................................128 11.4 Metodiske valg........................................................................................................................128 11.4.1 Antagelser i opgaven......................................................................................................128 11.4.2 Udelukkelse af svarkategorien ´Ikke relevant´...............................................................129 11.4.3 Selektionsbias og bortfald i undersøgelsen...................................................................129 11.5 Delkonklusion om datamateriale og metodevalg....................................................................131 12 Diskussion af skalavalideringens resultater...............................................................................132 12.1 Fortolkning af γ-koefficienterne..............................................................................................132 12.2 Logikken bag de lokale afhængigheder..................................................................................132 12.2.1 Homogenitet og lokal afhængighed................................................................................132 12.2.2 ’Response dependence’.................................................................................................133 12.2.3 Afsluttende kommentar til lokal afhængighed................................................................134 12.3 Betydningen af DIF.................................................................................................................134 12.4 Skalaernes validitet og skalerbarhed......................................................................................135 12.4.1 Begrebsvaliditet..............................................................................................................135 12.4.2 Kriterievaliditet................................................................................................................135 12.4.3 Sensitivitet......................................................................................................................136 12.4.4 Reliabilitet.......................................................................................................................136 12.4.5 Generaliserbarhed..........................................................................................................137 12.5 Afsluttende kommentarer til skalavalideringen.......................................................................137 12.6 Dimensioner af non-compliance.............................................................................................137 12.6.1 ´Utilsigtet non-compliance´.............................................................................................138 12.6.2 ´Tilsigtet non-compliance´..............................................................................................139 12.6.3 ´Handlekompetence´......................................................................................................139 12.6.4 ´Overskud´, ´praktiske problemer´ og ´medicinsk bekymring´ som supplement til ´handlekompetence´........................................................................................................................140 12.6.5 Under- og overmedicinering...........................................................................................142 12.7 Delkonklusion for skalaernes compliance-dimensioner..........................................................143 13 Diskussion af de multivariate analyser.......................................................................................145 13.1 Tolkning af resultater for multivariat analyse 1.......................................................................145 13.1.1 Enkelt-variable som compliance-variable.......................................................................145 13.1.2 MEMS compliance-variable............................................................................................146 13.1.3 PEM og skala compliance-variable................................................................................148 13.1.4 Opsummering af analyse 1............................................................................................150 13.2 Tolkning af resultater for multivariat analyse 2.......................................................................151 13.2.1 Enkelt-variable som compliance-variable.......................................................................151 13.2.2 MEMS compliance-variable............................................................................................151 13.2.3 PEM og skala compliance-variable................................................................................151 13.2.4 Opsummering af analyse 2............................................................................................152 13.3 Validiteten af de multivariate analyser....................................................................................153 13.3.1 Begrebsvaliditet for non-compliance..............................................................................153 13.3.2 Variablene kriterievalideres indbyrdes...........................................................................153 13.3.3 Selektionsbias’ påvirkning af validiteten.........................................................................153 13.3.4 Skalaernes sufficiens......................................................................................................154 13.4 Afsluttende kommentarer til den mulitvariate analyse............................................................155 14 Udvikling af screeningsredskab...................................................................................................156 14.1 Compliance variablenes relevans...........................................................................................156 14.2 Det simple og præcise screeningsredskab.............................................................................158 14.3 Screeningsredskabet..............................................................................................................160 14.4 Den praktiske anvendelse af screeningsredskabet................................................................161 15 Konklusion.....................................................................................................................................163 16 Perspektivering..............................................................................................................................164 7 17 Anvendte forkortelser og begreber..............................................................................................166 18 Litteraturliste..................................................................................................................................169 19 Bilag................................................................................................................................................173 8 Liste over tabeller Tabel 1: Screeningsmetoder til non-compliance........................................................................................22 Tabel 2: Udvalgte prædiktorer for non-compliance for hypertensionspatienter.........................................29 Tabel 3: Oversigt over IRT-modellernes egenskaber................................................................................46 Tabel 4: Udvalgte spørgeskemavariable....................................................................................................51 Tabel 5: Frasorterede spørgeskemavariable.............................................................................................56 Tabel 6: Fordeling af eksogene variable....................................................................................................76 Tabel 7: Fordeling af prædiktorvariable......................................................................................................77 Tabel 8: Krydstabel for variablene ´systolisk BT´ og ´diastolisk BT´..........................................................78 Tabel 9: Fordeling af compliance-variablene fra spørgeskemaerne..........................................................79 Tabel 10: Fordeling af PEM- og MEMS-data.............................................................................................80 Tabel 11: Fordeling af de kategoriserede PEM- og MEMS-data...............................................................81 Tabel 12: Fordelingen af besvarelser for ´problemer med medicinen´......................................................83 Tabel 13: Fordelingen af besvarelser for ´erfaringer med medicinen´.......................................................87 Tabel 14: Fordelingen af besvarelser for ´din psykiske trivsel´..................................................................93 Tabel 15: Fordelingen af besvarelser for ´din brug af medicin´..................................................................95 Tabel 16: Fordelingen af scorerne for skalaen ´utilsigtet non-compliance´.............................................109 Tabel 17: Fordelingen af scorerne for skalaen ´tilsigtet non-compliance´...............................................109 Tabel 18: Fordelingen af scorerne for skalaen ´handlekompetence´.......................................................110 Tabel 19: Fordelingen af besvarelserne for enkelt-variablene.................................................................110 Tabel 20: Fordelingen af scorerne for skalaen ´overskud´.......................................................................111 Tabel 21: Fordelingen af scorerne for skalaen ´praktiske problemer´.....................................................111 Tabel 22: Fordelingen af scorerne for skalaen ´medicinsk bekymring´...................................................112 Tabel 23: Krydstabel for PEM og score for ´tilsigtet non-compliance´.....................................................149 9 Liste over figurer Figur 1: Typer af non-compliance [efter Barber, 2002]..............................................................................18 Figur 2: Persistence for undersøgelsespopulationen beregnet vha. MEMS..............................................27 Figur 3: MEMS-målene for alle cases (n = 33)...........................................................................................80 Figur 4: Skalaen ´utilsigtet non-compliance´..............................................................................................90 Figur 5: Skalaen ´tilsigtet non-compliance´................................................................................................92 Figur 6: Skalaen ´handlekompetence´.......................................................................................................99 Figur 7: Skalaen ´overskud´.....................................................................................................................103 Figur 8: Skalaen ´praktiske problemer´....................................................................................................104 Figur 9: Skalaen ´medicinsk bekymring´..................................................................................................106 Figur 10: Komplet model for analyse 1.....................................................................................................116 Figur 11: Selekteret model for analyse 1..................................................................................................117 Figur 12: Komplet model for analyse 2.....................................................................................................120 Figur 13: Selekteret model for analyse 2..................................................................................................121 Figur 14: Illustration af screeningsredskabet............................................................................................160 10
Description: